Risedronic acid

Identification

Summary

Risedronic acid is a bisphosphonate used to treat osteoporosis and Paget's disease.

Brand Names

Actonel, Atelvia

Generic Name

Risedronic acid

DrugBank Accession Number

DB00884

Background

Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease^Label^1,2. It functions by preventing resorption of bone^Label¹.

Type

Small Molecule

Groups

Approved, Investigational

Structure

Similar Structures

Weight: Average: 283.1123
Monoisotopic: 283.001074735
Chemical Formula: C₇H₁₁NO₇P₂

Synonyms

Acide risédroniqe
Acido risedronico
Acidum risedronicum
Risedronate
Risedronic acid
Risedronsäure

External IDs

NE-58095

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis^Label.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics
Management of	Hypercalcemia of malignancy		••• •••••
Used in combination to prevent	Osteoporosis	Regimen in combination with: Calcium (DB01373), Cholecalciferol (DB00169)	••••••••••••	••••••••••••••
Used in combination to manage	Osteoporosis	Regimen in combination with: Calcium (DB01373), Cholecalciferol (DB00169)	••••••••••••	••••••••••••••
Treatment of	Osteoporosis		••••••••••••		•••••••••••••••
Treatment of	Osteoporosis		••••••••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Risedronate is a pyridine-based bisphosphonate that inhibits bone resorption caused by osteoclasts^Label.

Mechanism of action

Risedronatic acid binds to bone hydroxyapatite^Label. Bone resorption causes local acidification, releasing risedronic acid which is that taken into osteoclasts by fluid-phase endocytosis¹. Endocytic vesicles are acidified, releasing risedronic acid to the cytosol of osteoclasts where they induce apoptosis through inhbition of farnesyl pyrophosphate synthase¹. Inhibition of osteoclasts results in decreased bone resorption¹.

Target	Actions	Organism
AHydroxylapatite	antagonist	Humans
AFarnesyl pyrophosphate synthase	inhibitor	Humans

Absorption

Oral bioavailability is 0.63% and maximum absorption is approximately 1 hour after dosing^Label. Administration half and hour before a meal reduces bioavailability by 55% compared to fasting and dosing 1 hour before a meal reduces bioavailability by 30%^Label.

Volume of distribution

13.8 L/kg^Label.

Protein binding

~24%^Label.

Metabolism

Risedronic acid is not likely not metabolized before elimination^Label. The P-C-P group of bisphosphonates is resistant to chemical and enzymatic hydrolysis preventing metabolism of the molecule¹.

Route of elimination

Risedronate is excreted by the kidneys and the unabsorbed dose is eliminated in the feces^Label.

Half-life

The initial half life of risedronic acid is approximately 1.5 hours³, with a terminal half life of 561 hours^Label.

Clearance

Mean renal clearance was 52mL/min and mean total clearance was 73mL/min^Label.

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

In clinical trials, over 10% of patients experienced back pain, arthralgia, abdominal pain, and dyspepsia^Label. Less commonly, patients experience angioedema, generalized rash, bullous skin reactions, iritis, and uveitis^Label.

Patients experiencing an overdose may experience a decrease in serum calcium and phosphorus^Label. Patients can be given milk or antacids to bind the drug and reduce its absorption^Label. In more severe cases, patients may require gastric lavage and intravenous calcium^Label. A lethal dose in rats is equivalent to 320 to 620 times the human dose based on surface area^Label.

Pathways

Pathway	Category
Risedronate Action Pathway	Drug action

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Aceclofenac	The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Risedronic acid.
Acemetacin	The risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Risedronic acid.
Acetylsalicylic acid	The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Risedronic acid.
Acipimox	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Acipimox.
Acyclovir	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Risedronic acid.

Food Interactions

Administer vitamin supplements. Patients may require supplemental vitamin D.
Avoid multivalent ions. Calcium, antacids, and divalent ions may interfere with the absorption of this medication.
Take on an empty stomach.
Take with a full glass of water.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Risedronate sodium	OFG5EXG60L	115436-72-1	DRFDPXKCEWYIAW-UHFFFAOYSA-M
Risedronate sodium hemi-pentahydrate	HU2YAQ274O	329003-65-8	HYFDYHPNTXOPPO-UHFFFAOYSA-L
Risedronate sodium monohydrate	F67L43UT5C	353228-19-0	KLQNARDFMJRXSF-UHFFFAOYSA-M

Product Images

International/Other Brands

Benet (Takeda ) / Ridron

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Actonel	Tablet	35 mg	Oral	Abbvie	2002-12-10	Not applicable
Actonel	Tablet	5 mg	Oral	Allergan Pharma Co.	2000-07-25	2019-01-04
Actonel	Tablet	75 mg	Oral	Warner Chilcott	2007-08-13	2016-08-05
Actonel	Tablet, film coated	5 mg/1	Oral	Warner Chilcott	2000-04-14	Not applicable
Actonel	Tablet, film coated	75 mg/1	Oral	Warner Chilcott	2007-04-16	2010-03-31

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Aa-risedronate Dr	Tablet, delayed release	35 mg	Oral	Aa Pharma Inc	2021-05-18	Not applicable
Apo-risedronate	Tablet	35 mg	Oral	Apotex Corporation	2010-11-10	Not applicable
Apo-risedronate	Tablet	150 mg	Oral	Apotex Corporation	2012-05-17	Not applicable
Auro-risedronate	Tablet	30 mg	Oral	Auro Pharma Inc	Not applicable	Not applicable
Auro-risedronate	Tablet	35 mg	Oral	Auro Pharma Inc	2013-07-08	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Actonel	Risedronate sodium hemi-pentahydrate (129 mg/1) + Risedronate sodium monohydrate (21 mg/1)	Tablet, film coated	Oral	Allergan, Inc.	2008-04-22	Not applicable
Actonel	Risedronate sodium hemi-pentahydrate (30.1 mg/1) + Risedronate sodium monohydrate (4.9 mg/1)	Tablet, film coated	Oral	Allergan, Inc.	2002-05-17	Not applicable
Actonel	Risedronate sodium hemi-pentahydrate (25.8 mg/1) + Risedronate sodium monohydrate (4.2 mg/1)	Tablet, film coated	Oral	Allergan, Inc.	1998-03-27	2020-02-28
Actonel	Risedronate sodium hemi-pentahydrate (64.5 mg/1) + Risedronate sodium monohydrate (10.5 mg/1)	Tablet, film coated	Oral	Allergan, Inc.	2007-04-16	2010-03-31
Actonel	Risedronate sodium hemi-pentahydrate (30.1 mg/1) + Risedronate sodium monohydrate (4.9 mg/1)	Tablet, film coated	Oral	Allergan, Inc.	2002-05-17	Not applicable

Chemical Identifiers

UNII: KM2Z91756Z
CAS number: 105462-24-6
InChI Key: IIDJRNMFWXDHID-UHFFFAOYSA-N
InChI: InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
IUPAC Name: [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid
SMILES: OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O

References

Synthesis Reference

Srinivasa Rao V.N Divvela, Lenin Racha, Sivakumaran Meenakshisunderam, Ramesh Dandala, "Process for the preparation of risedronate sodium hemi-pentahydrate." U.S. Patent US20070173484, issued July 26, 2007.

US20070173484

General References

Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. [Article]
Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28. [Article]
Thompson Micromedex (2004). Usp Vol I Drug Info Health Vol: Volume I (USP DI: v.1 Drug Information for the Health Care Professional) (24th ed., pp. 2475). Thompson PDR. [ISBN:1563634635]
Risedronate Sodium Tablet MSDS [Link]
FDA Approved Drugs: Risedronic Acid Oral Tablets [Link]
FDA Approved Drug Products: Risedronic Acid Extended Release Tablets [Link]

External Links

Human Metabolome Database: HMDB0015022
KEGG Drug: D08484
KEGG Compound: C08233
PubChem Compound: 5245
PubChem Substance: 46507526
ChemSpider: 5055
BindingDB: 12576
RxNav: 55685
ChEBI: 8869
ChEMBL: CHEMBL923
ZINC: ZINC000001531009
Therapeutic Targets Database: DAP000658
PharmGKB: PA451255
PDBe Ligand: RIS
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Risedronic_acid

PDB Entries

1rqj / 1yhl / 1yq7 / 1yv5 / 2o1o / 2qis / 4kpd / 4kqs / 4n9u / 4ng6 …

show 9 more

FDA label

Download (229 KB)

MSDS

Download (69.7 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Not Available	Crohn's Disease (CD) / Decreased bone mineral density	1
4	Completed	Prevention	Bone Fractures / Bone Loss / Epilepsy / Osteoporosis	1
4	Completed	Prevention	Bone Loss / Breast Cancer / Osteoporosis	1
4	Completed	Prevention	Cystic Fibrosis (CF) / Duchenne Muscular Dystrophy (DMD) / Osteoporosis	1
4	Completed	Prevention	Postmenopausal Osteoporosis	1

Pharmacoeconomics

Manufacturers

Warner chilcott co llc
Teva pharmaceuticals usa
Procter & Gamble

Packagers

Diversified Healthcare Services Inc.
Lake Erie Medical and Surgical Supply
Murfreesboro Pharmaceutical Nursing Supply
Norwich Pharmaceuticals Inc.
Physicians Total Care Inc.
Procter & Gamble
Resource Optimization and Innovation LLC
Stat Rx Usa
Warner Chilcott Co. Inc.
WC Pharmaceuticals

Dosage Forms

Form	Route	Strength
Tablet, film coated	Oral	35 mg
Tablet, effervescent
Tablet	Oral	75 mg
Tablet, film coated	Oral	150 mg/1
Tablet, film coated	Oral	30 mg/1
Tablet, film coated	Oral	35 mg/1
Tablet, film coated	Oral	5 mg/1
Tablet, film coated	Oral	75 mg/1
Tablet, film coated	Oral	30 MG
Tablet, film coated	Oral	75 MG
Tablet, delayed release	Oral	35 mg
Tablet, coated	Oral	150 mg
Tablet, film coated	Oral	150 mg
Granule, effervescent; kit; tablet	Oral
Tablet, film coated	Oral	5 mg
Kit	Oral
Tablet	Oral	35.000 mg
Tablet	Oral	150 mg
Tablet, delayed release	Oral
Tablet, effervescent		150 mg
Tablet, effervescent		75 mg
Tablet, coated	Oral
Tablet	Oral
Tablet	Oral	35.00 mg
Tablet, film coated	Oral
Tablet, delayed release	Oral	35 mg/1
Tablet, film coated	Oral
Powder	Not applicable	1 kg/1kg
Tablet	Oral
Tablet, effervescent	Oral
Tablet	Oral	5.000 mg
Tablet	Oral	30 mg
Tablet	Oral	35 mg
Tablet	Oral	5 mg
Kit; tablet	Oral
Tablet, coated	Oral	35 mg

Prices

Unit description	Cost	Unit
Actonel 150 mg tablet	125.1USD	tablet
Actonel 4 35 mg tablet Disp Pack	119.43USD	disp
Actonel 75 mg tablet	54.83USD	tablet
Actonel 30 mg tablet	29.32USD	tablet
Actonel 35 mg tablet	28.75USD	tablet
Actonel 5 mg tablet	4.13USD	tablet
Actonel with calcium tablet	3.92USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6096342	No	2000-08-01	2011-11-22
CA2294595	No	2001-08-21	2018-07-17
CA2399976	No	2007-03-27	2021-02-01
US7192938	Yes	2007-03-20	2023-11-06
US7718634	Yes	2010-05-18	2023-11-06
US6165513	Yes	2000-12-26	2018-12-10
US5994329	Yes	1999-11-30	2019-01-17
US6015801	Yes	2000-01-18	2019-01-17
US6432932	Yes	2002-08-13	2019-01-17
US6465443	Yes	2002-10-15	2019-02-14
US7645459	No	2010-01-12	2028-01-09
US7645460	No	2010-01-12	2028-01-09
US8246989	No	2012-08-21	2026-01-16

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	252-262	https://www.greenstonellc.com/sites/default/files/pdfs/MSDS/RISEDRONATE%20SODIUM%20TABLETS%20MSDS_0.pdf
boiling point (°C)	692.3	https://www.greenstonellc.com/sites/default/files/pdfs/MSDS/RISEDRONATE%20SODIUM%20TABLETS%20MSDS_0.pdf

Predicted Properties

Property	Value	Source
Water Solubility	10.4 mg/mL	ALOGPS
logP	-0.75	ALOGPS
logP	-3.3	Chemaxon
logS	-1.4	ALOGPS
pKa (Strongest Acidic)	0.68	Chemaxon
pKa (Strongest Basic)	4.91	Chemaxon
Physiological Charge	-3	Chemaxon
Hydrogen Acceptor Count	8	Chemaxon
Hydrogen Donor Count	5	Chemaxon
Polar Surface Area	148.18 Å²	Chemaxon
Rotatable Bond Count	4	Chemaxon
Refractivity	57.12 m³·mol^-1	Chemaxon
Polarizability	21.91 Å³	Chemaxon
Number of Rings	1	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	-	0.9357
Blood Brain Barrier	+	0.9172
Caco-2 permeable	-	0.6795
P-glycoprotein substrate	Non-substrate	0.6846
P-glycoprotein inhibitor I	Non-inhibitor	0.9582
P-glycoprotein inhibitor II	Non-inhibitor	1.0
Renal organic cation transporter	Non-inhibitor	0.9542
CYP450 2C9 substrate	Non-substrate	0.8452
CYP450 2D6 substrate	Non-substrate	0.8162
CYP450 3A4 substrate	Non-substrate	0.7208
CYP450 1A2 substrate	Non-inhibitor	0.8778
CYP450 2C9 inhibitor	Non-inhibitor	0.8792
CYP450 2D6 inhibitor	Non-inhibitor	0.9062
CYP450 2C19 inhibitor	Non-inhibitor	0.8777
CYP450 3A4 inhibitor	Non-inhibitor	0.9068
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.989
Ames test	Non AMES toxic	0.7663
Carcinogenicity	Non-carcinogens	0.8386
Biodegradation	Not ready biodegradable	0.5058
Rat acute toxicity	2.1053 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9095
hERG inhibition (predictor II)	Non-inhibitor	0.9303

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-001l-9030000000-834cccb13596d4a6e4c2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0ue9-0490000000-57ddb91ff8ccb149a8a2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-001i-0790000000-c2a233ca5a42b3cdd925
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-001i-0090000000-f4a556d28a85f9424b04
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-03fr-9030000000-dea17b00a079a831b2c2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00kf-9100000000-a8daf608efb1da969f9c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-03fr-9010000000-02449ab92bded9025cc5
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	161.6330857	predicted	DarkChem Lite v0.1.0
[M-H]-	144.6663	predicted	DeepCCS 1.0 (2019)
[M+H]+	160.9833857	predicted	DarkChem Lite v0.1.0
[M+H]+	147.06187	predicted	DeepCCS 1.0 (2019)
[M+Na]+	160.4181857	predicted	DarkChem Lite v0.1.0
[M+Na]+	153.03542	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Hydroxylapatite

Kind

Small molecule

Organism

Humans

Pharmacological action

Yes

Actions

Antagonist

References

Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [Article]
Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [Article]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	10	N/A	N/A	A27595 / A27598
IC 50 (nM)	170	N/A	N/A	A27596
IC 50 (nM)	452.9	N/A	N/A	A27597
IC 50 (nM)	5.7	N/A	N/A	A27597 / A29182
IC 50 (nM)	300	N/A	N/A	A29183
IC 50 (nM)	11	N/A	N/A	A28083 / A29184
IC 50 (nM)	860	N/A	N/A	A28083
Ki (nM)	16	N/A	N/A	A27596
Ki (nM)	0.36	N/A	N/A	A27597
Ki (nM)	82.2	N/A	N/A	A27597

Details2. Farnesyl pyrophosphate synthase

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Poly(a) rna binding
Specific Function: Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name: FDPS
Uniprot ID: P14324
Uniprot Name: Farnesyl pyrophosphate synthase
Molecular Weight: 48275.03 Da

References

Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [Article]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ: Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005 Sep;37(3):349-58. [Article]
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [Article]
Ortiz-Gomez A, Jimenez C, Estevez AM, Carrero-Lerida J, Ruiz-Perez LM, Gonzalez-Pacanowska D: Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell. 2006 Jul;5(7):1057-64. [Article]
Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57. [Article]

Enzymes

Details1. Prostaglandin G/H synthase 2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inducer

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name: PTGS2
Uniprot ID: P35354
Uniprot Name: Prostaglandin G/H synthase 2
Molecular Weight: 68995.625 Da

References

Valenti MT, Giannini S, Donatelli L, Zanatta M, Bertoldo F, Sella S, Vilei MT, Ossi E, Realdi G, Lo Cascio V, Dalle Carbonare L: The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther. 2010;12(4):R163. doi: 10.1186/ar3122. Epub 2010 Aug 25. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55

Risedronic acid

Identification

Structure for Risedronic acid (DB00884)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

References

Enzymes

References